en · de · es · fr · pt
field-notes.peptides3626.com › Guide › Regulation, Testing, And Storage — Research Overview

Regulation, Testing, And Storage — Research Overview

By Editorial Desk · published 2025-07-19 · last reviewed 2025-08-28 · Guide

Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Background and Receptor Pharmacology

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.

Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.

Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.

Sr9009 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicine in major jurisdictionsSold as a research chemical; legal status varies
Anti-doping statusProhibited by the World Anti-Doping AgencyListed under non-approved substances or related category
Typical analytical methodLC-MS/MSUsed for detection and confirmation in biological samples
Storage temperature−20 °C or lower for solidDesiccated and protected from light
Common solution solventsDMSO; ethanolAqueous solubility is limited

Analytical Detection and Storage

Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Related pages on this site

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

Background from the literature

In 1969, the Dubna team carried out chemical experiments on element 102 and concluded that it behaved as the heavier homologue of ytterbium. The Russian scientists proposed the name joliotium (Jo) for the new element after Irène Joliot-Curie, who had recently died, creating an element naming controversy that would not be resolved for several decades, with each group using its own proposed names. In 1992, the IUPAC-IUPAP Transfermium Working Group (TWG) reassessed the claims of discovery and concluded that only the Dubna work from 1966 correctly detected and assigned decays to nuclei with atomic number 102 at the time. The Dubna team are therefore officially recognized as the discoverers of nobelium, although it is possible that it was detected at Berkeley in 1959. This decision was criticized by Berkeley the following year, calling the reopening of the cases of elements 101 to 103 a "futile waste of time", while Dubna agreed with IUPAC's decision. In 1994, as part of an attempted resolution to the element naming controversy, IUPAC ratified names for elements 101–109. For element 102, it ratified the name nobelium (No) on the basis that it had become entrenched in the literature over the course of 30 years and that Alfred Nobel should be commemorated in this fashion. Because of outcry over the 1994 names, which mostly did not respect the choices of the discoverers, a comment period ensued, and in 1995 IUPAC named element 102 flerovium (Fl) as part of a new proposal, after either Georgy Flyorov or his eponymous Flerov Laboratory of Nuclear Reactions.

3 August – Dogxim, the now-dead first known hybrid of a fox and a domesticated dog, discovered in the wild in Brazil in 2021, is reported. 8 August Walking more than 3,967 steps each day is shown to reduce the risk of dying prematurely of any cause, based on a study of 226,000 people around the world. This is considerably less than previous recommendations, which have sometimes cited a figure of 10,000+ steps being needed each day. A study shows activating astrocyte cells in mice with a novel technique makes them stay awake for much longer without making them sleepier or impacting cognition-associated EEG markers. 10 August – Scientists at Fermilab report the most precise measurement yet of the magnetic moment of the muon. The particles are shown to wobble faster than predicted by the Standard Model, hinting at a possible fifth fundamental force. 11 August The rise in photosynthesis rates around the world caused by the increase of carbon dioxide is found to have slowed dramatically in the 21st century, as the atmosphere has grown drier. A global consortium releases two studies and a database on DNA methylation profiles across 348 mammalian species for use in epigenetic clocks. They provide various new results relating to human aging and animal experiments as well as predictive models that can estimate mammalian tissue age or risk with high accuracy. On 16 August, a study indicates chest radiographs evaluated using AI could be a performant biomarker for aging clocks.

According to 2023 V-Dem Democracy indices Ghana is ranked 67th electoral democracy worldwide and 10th electoral democracy in Africa. Ghana is a country in West Africa that is known for its cultural diversity, democratic government, and growing economy. The country has more than 30 million people and is home to many ethnic groups, languages, and traditions. Ghana is one of the world's leading producers of cocoa and is also rich on natural resources such as oil and gold. Besides economic importance, Ghana is recognized for its peaceful elections, historic landmarks, national parks and contributions to regional development in West Africa.

Sources: en.wikipedia.org

Further detail

Data from the Moneyfacts Group suggests the average rate on a two-year fixed-term mortgage has fallen below 6% for the first time since June 2023. The Court of Session in Edinburgh rules that the UK government acted lawfully by blocking the Gender Recognition Reform (Scotland) Bill from becoming law, and rejects the Scottish Government's appeal against the decision. At the Old Bailey, Paul Bryan is sentenced to life imprisonment with a minimum of 24 years for the 1984 murder of Roman Szalajko at the victim's south London home. Bryan assumed the identity of a dead man with the same name, but was traced through a fingerprint match in 2022. After footballer Joey Barton suggests that women "should not be talking with any kind of authority" about men's football, Chelsea manager Emma Hayes says women are "routinely used to dealing with systemic misogyny and bullying" in football. Wham!'s Last Christmas tops the singles chart for the fourth time with Mariah Carey's All I Want For Christmas Is You taking the second spot. A week after the death of Shane MacGowan from The Pogues, Fairytale of New York rises to number four. 9 December Yellow weather warnings are in place for much of the UK as two successive storms, Elin and Fergus, reach the UK from the Atlantic, bringing high winds and heavy rain. The royal family reveal their Christmas card images with King Charles III choosing a photograph from his coronation earlier this year for his second Christmas as monarch.

=== Drug discovery === One major outcome of research on human genes and proteins has been the identification of potential new drugs for the treatment of disease. This process relies on genome and proteome information to identify proteins associated with specific diseases, which can then be evaluated as therapeutic targets using computational approaches. For example, when a protein is implicated in a disease, knowledge of its three-dimensional structure can guide the design of drugs that interfere with its function. A molecule that fits into the active site of an enzyme but cannot be released can effectively inactivate the enzyme. This principle underlies many modern drug-discovery strategies, which aim to identify compounds capable of modulating or inhibiting disease-relevant proteins. As genetic differences among individuals are increasingly characterized, these approaches are expected to support the development of personalized medicines tailored to improve efficacy for individual patients. A branch of proteomics known as chemoproteomics provides a broad set of tools and techniques for identifying and characterizing the protein targets of drugs, thereby supporting drug discovery and development efforts.

== External links == Human CSN3 genome location and CSN3 gene details page in the UCSC Genome Browser. InterPro: IPR000117 Kappa casein Fluorescein Thiocarbamoyl-Kappa-Casein Assay for the Specific Testing of Milk-Clotting Proteases Biotechnology and Microbiology

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

How is SR9009 detected?

Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.

How should SR9009 be stored?

Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.

What is SR9009?

SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.

Network